Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Sell Facility to HGS in $55M Cash Deal

NEW YORK, March 9 - Invitrogen has sold its Rockville, Md., facility to Human Genome Sciences for $55 million in cash, the company said Friday.

Invitrogen acquired the 240,000 square foot facility in its September 2000 acquisition of Life Technologies, which had it headquarters located at the facility. Invitrogen occupies facilities in five other locations, including a manufacturing site in Frederick County, Md.

"Although this property transaction is part of our effort to sell surplus assets following our acquisition of Life Technologies, it also plays a more strategic role," said Invitrogen CEO Lyle Turner in a statement. "Our objective with this property sale is to more effectively organize and integrate Invitrogen's functional groups with those that came to us from Life Technologies, and to further instill Invitrogen's culture into the combined organization."

Invitrogen also hopes to lower its operating costs through this consolidation, Turner said.

Invitrogen and HGS expect to close the sale by the end of April, but Invitrogen is not expecting to finish moving out of the Rockville facility until the end of the year.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.